BSECompany Update23 Jun 2026 · 23 Jun 2026, 08:37 pm
Disclosure under regulation 29 (2) of SEBI (SAST) Regulations, 2011
Goldline Pharmaceutical Ltd · 544759
✦ AI Summary▲ Positive
Goldline Pharmaceutical Ltd announced that its Promoter and Whole Time Director, Mr. Swapan Khandelwal, acquired 60,000 equity shares, representing 0.62% of the total paid-up share capital, through open market purchases on June 22, 2026. This disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Analysis Scores
Earnings Impact5/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk5/10
Liquidity Impact5/10
Market Sentiment7/10
Full Announcement
Goldline Pharmaceutical Ltd - 544759 - Disclosure Under Regulation 29 (2) Of Securities And Exchange Board Of India (Substantial Acquisition Of Shares And Takeovers) Regulations, 2011